Rezolute, INC Form 4 insider transactions

Rezolute, Inc. Director and 10% Owner, Young-Jin Kim, reported the acquisition of 9,000 restricted stock units and 5,000 stock options, aligning his interests with the company's future performance.

Rezolute, Inc.'s Chief Financial Officer, Daron Evans, has reported the acquisition of 26,000 restricted stock units and 15,000 employee stock options, signaling increased long-term alignment with shareholder interests.

Rezolute, Inc. Director Philippe Fauchet was granted 9,000 restricted stock units and 5,000 stock options on June 10, 2025, as part of his compensation.

Rezolute, Inc.'s Chief Medical Officer, Brian Kenneth Roberts, received grants of 26,000 restricted stock units and 15,000 employee stock options on June 10, 2025, as part of his compensation package.

Rezolute, Inc. CEO and Director Nevan C. Elam was granted 68,000 restricted stock units and 40,000 employee stock options on June 10, 2025, as part of his compensation package.

Director Wladimir Hogenhuis reports purchasing 6,758 common shares of Rezolute, Inc. at $2.92 per share.

Rezolute, Inc. CEO Nevan C. Elam purchased 12,302 shares of the company's common stock at an average price of $2.845 on March 27, 2025.

Daron Evans, CFO of Rezolute, Inc., reports purchasing 10,000 common shares at $2.89 and another 10,000 common shares at $2.88 on March 26, 2025, increasing his direct and indirect holdings.

Director Erik Harris of Rezolute, Inc. reports the acquisition of stock options.

Director Wladimir Hogenhuis reports acquisition of Rezolute stock and stock options, along with disposition of shares.

Director Gil M. Labrucherie reports the acquisition of restricted stock units and stock options in Rezolute, Inc.

CFO Daron Evans reports the grant of restricted stock units and stock options in Rezolute, Inc.

Director Nerissa Kreher reports acquisition of 25,500 common shares and 15,000 stock options in Rezolute, Inc.

Director Kim Young-Jin reports acquisition of Rezolute shares and stock options, including a significant purchase held indirectly through Handok, Inc.

Chief Medical Officer Brian Kenneth Roberts reports acquisition of Rezolute Inc. stock and options.

Rezolute, Inc. CEO Nevan C. Elam reports the acquisition of 204,000 common shares and 120,000 stock options.

Philippe Fauchet, a director at Rezolute, Inc., reports the acquisition of common shares and stock options.

Rezolute's CFO, Daron Evans, purchased 10,000 shares of the company's common stock at an average price of $4.29 per share on December 18, 2024.

Rezolute CFO Daron Evans reports a series of share transactions, including acquisitions and disposals, on December 12, 2024.

Rezolute's CFO, Daron Evans, purchased 10,549 common shares at a weighted average price of $5.04, increasing his holdings.

Director Wladimir Hogenhuis reports a transaction involving Rezolute, Inc. common stock on September 24, 2024.

CFO of Rezolute, Daron Evans, reports the acquisition of 100,000 employee stock options.

Director Wladimir Hogenhuis reports the acquisition of 4,815 shares of Rezolute, Inc. common stock at a price of $4.15 on June 25, 2024.

Brian Kenneth Roberts, Chief Medical Officer of Rezolute, Inc., reported purchasing shares of the company's stock on June 14, 2024.

Rezolute, Inc. CFO Daron Evans reports the acquisition of 40,000 common shares at an average price of $4.0392 on June 14, 2024.

CFO Daron Evans recently acquired 451 common shares of Rezolute, Inc. at $3.5 per share, increasing his direct holdings to 121,351 shares.

Brian Kenneth Roberts, Chief Medical Officer of Rezolute, Inc., reports acquiring common shares through open market purchases.

CFO Daron Evans reports purchases and disposals of Rezolute, Inc. shares, including those held directly, indirectly through a spouse, and for minor children.

Brian Kenneth Roberts, Chief Medical Officer of Rezolute, Inc., reported purchasing 500 shares of common stock at $2.55 per share on March 28, 2024.

Handok, Inc., a director and 10% owner of Rezolute, Inc., reports changes in beneficial ownership of common shares through open market transactions.